Ro24-7429 - ≥98% , Human immunodeficiency virus type 1 Tat protein antagonist, CAS No.139339-45-0, Human immunodeficiency virus type 1 Tat protein antagonist
En stock
SKU
R651352
Ro24-7429 is a potent and orally active HIV-1 transactivator protein Tat antagonist. Ro24-7429 is also a runt-related transcription factor 1 (RUNX1) inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects
In Vitro
Ro 24-7429 (0.1-5 μM; 3 days) induces apoptosis of cultured PBMCs in a dose-dependent manner. ?\nRo 24-7429 (1-25 μM) also induces apoptosis and inhibits antigen-induced lymphocyte proliferation. ?\nRo24-7429 (50-200 μM; 24-72 hours) strongly inhibits the proliferation of A549 and HLF cells in a dose-dependent manner. Ro24-7429 treatment (75 μM) significantly reduces TNF-α-induced up-regulation of RUNX1 mRNA by 50% at 48 hours. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: Peripheral blood mononuclear cells (PBMCs) Concentration: 0.1 μM, 1 μM, 5 μM Incubation Time: 3 days Result: Induced a dose-dependent increase in apoptosis of cultured PBMCs.
In Vivo
Ro24-7429 (17.5-70 mg/kg; i.p.; daily; for 14 or 21 days) treatment robustly ameliorates lung fibrosis and inflammation in the Bleomycin-induced pulmonary fibrosis (PF) mouse model. Ro24-7429 curbs expression of fibrosis markers in injured mouse lungs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J male and female mice (aged 6 to 8 weeks) induced by BleomycinDosage: 17.5 mg/kg, 35 mg/kg, and 70 mg/kg Administration: i.p.; daily; for 14 or 21 days Result: Ameliorated lung fibrosis and inflammation in the Bleomycin-induced PF mouse model.
Form:Solid
IC50& Target:HIV-1
Plus d’information
| CAS | 139339-45-0 |
|---|---|
| Spécifications et pureté | ≥98% |
| Conditions de stockage de stockage | Store at -20°C |
| Expédié en | Ice chest + Ice pads |
| Product Description | Ro24-7429 is a potent and orally active HIV-1 transactivator protein Tat antagonist. Ro24-7429 is also a runt-related transcription factor 1 (RUNX1) inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects In Vitro Ro 24-7429 (0.1-5 μM; 3 days) induces apoptosis of cultured PBMCs in a dose-dependent manner. ?\nRo 24-7429 (1-25 μM) also induces apoptosis and inhibits antigen-induced lymphocyte proliferation. ?\nRo24-7429 (50-200 μM; 24-72 hours) strongly inhibits the proliferation of A549 and HLF cells in a dose-dependent manner. Ro24-7429 treatment (75 μM) significantly reduces TNF-α-induced up-regulation of RUNX1 mRNA by 50% at 48 hours. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: Peripheral blood mononuclear cells (PBMCs) Concentration: 0.1 μM, 1 μM, 5 μM Incubation Time: 3 days Result: Induced a dose-dependent increase in apoptosis of cultured PBMCs. In Vivo Ro24-7429 (17.5-70 mg/kg; i.p.; daily; for 14 or 21 days) treatment robustly ameliorates lung fibrosis and inflammation in the Bleomycin-induced pulmonary fibrosis (PF) mouse model. Ro24-7429 curbs expression of fibrosis markers in injured mouse lungs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J male and female mice (aged 6 to 8 weeks) induced by BleomycinDosage: 17.5 mg/kg, 35 mg/kg, and 70 mg/kg Administration: i.p.; daily; for 14 or 21 days Result: Ameliorated lung fibrosis and inflammation in the Bleomycin-induced PF mouse model. Form:Solid IC50& Target:HIV-1 |
| Solubilité | DMSO : 62.5 mg/mL (229.16 mM; Need ultrasonic) |
Avis
Avis des clients
Nous avons trouvé d’autres produits qui pourraient vous intéresser !
-
Ro24-7429, Human immunodeficiency virus type 1 Tat protein antagonistÀ partir de 399,90 $US
Remind me later